A phase I trial in HIV negative healthy volunteers evaluating the effect of potent adjuvants on immunogenicity of a recombinant gp120(W61D) derived from dual tropic R5X4 HIV-1(ACH320)

Vaccine

Volumn 18, Issue 13, 2000, Pages 1166-1177

  McCormack, S ^a   Tilzey, A ^b   Carmichael, A ^c   Gotch, F ^d   Kepple, J ^e   Newberry, A ^a   Jones, G ^e   Lister, S ^e   Beddows, S ^e   Cheingsong, R ^e   Rees, A ^e   Babiker, A ^a   Banatvala, J ^b   Bruck, C ^f   Darbyshire, J ^a   Tyrrell, D ^g   Van Hoecke, C ^f   Weber, J ^e  

^a Med Res Cncl Clinical Trials Unit   (United Kingdom)

^b ST THOMAS HOSPITAL   (United Kingdom)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^d CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

^e IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

^f GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

^g PUBLIC HEALTH ENGLAND   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN GP 120; IMMUNOLOGICAL ADJUVANT; PHOSPHORYL LIPID A; QS 21; RECOMBINANT GLYCOPROTEIN GP 120; UNCLASSIFIED DRUG;

ADULT; ANTIBODY TITER; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DRUG POTENCY; FEMALE; FEVER; HEADACHE; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOGENICITY; IMMUNOMODULATION; INJECTION PAIN; LYMPHOCYTE PROLIFERATION; MALAISE; MALE; MYALGIA; NAUSEA; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; T LYMPHOCYTE SUBPOPULATION;

ADJUVANTS, IMMUNOLOGIC; ADULT; AIDS VACCINES; FEMALE; FOLLOW-UP STUDIES; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP120; HIV SERONEGATIVITY; HIV-1; HUMANS; IMMUNIZATION SCHEDULE; LIPID A; MALE; NEUTRALIZATION TESTS; VACCINES, SYNTHETIC;

EID: 0033988471     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(99)00388-6     Document Type: Article

References (39)

1. De Cock K.M., Churchill D., Grant A., Del Amo J., Rouleau D., Zala C., et al. Summary of track B: clinical science. AIDS. 10:(Suppl. 3):1996;S107-S113.
2. IIIB rgp120 subunit vaccine. Lancet. 342:1993;69-73.
3. Belshe R.B., Graham B.S., Keefer M.C., Gorse G.J., Wright P., Dolin R., et al. Neutralizing antibodies to HIV-1 in seronegative volunteers immunized with recombinant gp120 from the MN strain of HIV-1. NIAID AIDS Vaccine Clinical Trials Network. J. Am. Med. Ass. 272:(6):1994;475-480.
4. Keefer M.C., Graham B.S., Belshe R.B., Schwartz D., Corey L., Bolognesi D.P., et al. Studies of high doses of a human immunodeficiency virus type 1 recombinant glycoprotein 160 candidate vaccine in HIV type 1-seronegative humans. The AIDS Vaccine Clinical Trials Network. AIDS Res. Hum. Retroviruses. 10:(12):1994;1713-1723.
5. Belshe R.B., Clements M.L., Dolin R., Graham B.S., McElrath J., Gorse G.J., et al. Safety and immunogenicity of a fully glycosylated recombinant gp160 human immunodeficiency virus type 1 vaccine in subjects at low risk of infection. J. Infect. Dis. 168:(6):1993;1387-1395.
6. Salmon-Céron D., Excler J.-L., Sicard D., Blanche P., Finkielstzjen L., Gluckman J.-C., et al. Safety and immunogenicity of a recombinant HIV type 1 glycoprotein 160 boosted by a V3 synthetic peptide in HIV-negative volunteers. AIDS Res. Hum. Retroviruses. 11:(12):1995;1479-1486.
7. Graham B.S., Belshe R.B., Clements M.L., Dolin R., et al. Vaccination of Vaccinia-Naive adults with HIV Type 1 gp160 recombinant Vaccinia virus in a blinded, controlled, randomized clinical trial. J. Infect. Dis. 166:1992;244-252.
8. Pialoux G., Excler J.-L., Riviére Y., Gonzalez-Canali G., Feuillie V., Coulaud P., et al. A prime-boost approach to HIV preventive vaccine using a recombinant canarypox virus expressing glycoprotein 160 (MN) followed by a recombinant glycoprotein 160 (MN/LAI). AIDS Res. Hum. Retroviruses. 11:(3):1995;373-381.
9. Cooney E.L., Collier A.C., Greenberg P.D., Coombs R.W., Zarling J., Arditti D.E., et al. Safety of and immunological response to a recombinant vaccinia virus vaccine expressing HIV envelope glycoprotein. Lancet. 337:(8741):1991;567-572.
10. Keefer M.C., Wolff M., Gorse G.J., Graham B.S., Corey L., Clements-Mann M.L., et al. Safety profile of phase I and phase II preventive HIV type 1 envelope vaccination: experience of the NIAID AIDS Vaccine Evaluation Group. AIDS Res. Hum. Retroviruses. 13:(14):1997;1163-1177.
11. Keefer M.C., Graham B.S., McElrath M.J., Matthews T.J., Stablein D.M., Corey L., et al. Safety and immunogenicity of Env 2-3, a human immunodeficiency virus type 1 candidate vaccine, in combination with a novel adjuvant, MTP-PE/MF59. AIDS Res. Hum. Retroviruses. 12:(8):1996;683-693.
12. Graham B.S., Matthews T.J., Belshe R.B., Clements M.L., Dolin R., Wright P.F., et al. Augmentation of human immunodeficiency virus type 1 neutralizing antibody by priming with gp160 recombinant vaccinia and boosting with rgp160 in vaccinia-naive adults. The NIAID AIDS Vaccine Clinical Trials Network. J. Infect. Dis. 167:(3):1993;533-537.
13. Corey L., McElrath M.J., Weinhold K., Matthews T., Stablein D., Graham B., et al. Cytotoxic T Cell and neutralizing antibody responses to human immunodeficiency virus type 1 envelope with a combination vaccine regimen. J. Infect. Dis. 177:1998;301-309.
14. Perales M.-A., Schwartz D.H., Fabry J.A., Lieberman J. A vaccinia-gp160-based vaccine but not a gp160 protein vaccine elicits anti-gp160 cytotoxic T lymphocytes in some HIV-1 seronegative vaccinees. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 10:(1):1995;27-35.
15. Keefer M.C., Belshe R.B., Graham B.S., McElrath M.J., Clements M.L., Sposto R., et al. Phase I/II trials of preventive HIV vaccine candidates - safety profile of HIV vaccination: first 1000 volunteers of AIDS vaccine evaluation group. AIDS Res. Hum. Retroviruses. 10:(Suppl. 2):1994;S139-140.
16. McElrath M.J., Corey L., Greenberg P.D., Matthews T.J., Montefiori D.C., Rowen L., et al. Human immunodeficiency virus type 1 infection despite prior immunization with a recombinant envelope vaccine regimen. Proc. Natl. Acad. Sci. USA. 93:(9):1996;3972-3977.
17. Kahn J.O., Steimer K.S., Baenziger J., Duliege A.M., Feinberg M., Elbeik T., et al. Clinical, immunologic, and virologic observations related to human immunodeficiency virus (HIV) type 1 infection in a volunteer in an HIV-1 vaccine clinical trial. J. Infect. Dis. 171:(5):1995;1343-1347.
18. Mooij P., van der Kolk M., Bogers W.M., ten Haaft P.J., Van Der Meide P., Almond N., et al. A clinically relevant HIV-1 subunit vaccine protects rhesus macaques from in vivo passaged simian-human immunodeficiency virus infection. AIDS. 12:(5):1998;F15-F22.
19. Groenink M., Fouchier R.A.M., de Goede R.E.Y., de Wolf F., Gruters R.A., Cuypers H.T.M., et al. Phenotypic heterogeneity in a panel of infectious molecular human immunodeficiency virus type 1 clones derived from a single individual. J. Virol. 65:(4):1991;1968-1975.
20. Groenink M., Andeweg A.C., Fouchier R.A.M., Broersen S., van der Jagt R.C.M., Schuitemaker H., et al. Phenotype-associated env gene variation among eight related human immunodeficiency virus type 1 clones: evidence for in vivo recombination and determinants of cytotropism outside the V3 domain. J. Virol. 66:(10):1992;6175-6180.
21. Beddows S., Lister S., Cheingsong-Popov R., Bruck C., Weber J. Comparison of the antibody repertoire generated in healthy volunteers following immunization with a monomeric recombinant gp120 construct derived from a CCR5/CXCR4 - using human immunodeficiency virus type 1 isolate with sera from naturally infected individuals. J. Virol. 73:(2):1998;1740-1745.
22. Cheingsong-Popov R., Lister S., Callow D., Kaleebu P., Beddows S., Weber J. Serotyping HIV type 1 by antibody binding to the V3 loop: relationship to viral genotype. AIDS Res. Hum. Retroviruses. 10:(11):1994;1379-1386.
23. Moore J.P. Simple methods for monitoring HIV-1 and HIV-2 gp120 binding to soluble CD4 by enzyme-linked immunosorbent assay: HIV-2 has a 25-fold lower affinity than HIV-1 for soluble CD4. AIDS. 4:1990;297-305.
24. Cheingsong-Popov R., Callow D., Beddows S., Shaunak S., Wasi C., Kaleebu P., et al. Geographic diversity of human immunodeficiency virus type 1: serologic reactivity to env epitopes and relationship to neutralization. J. Infect. Dis. 165:(2):1992;256-261.
25. Beddows S., Louisirirotchanakul S., Cheingsong-Popov R., Easterbrook P.J., Simmonds P., Weber J. Neutralisation of primary and T-cell line adapted isolates of human immunodeficiency virus type 1: role of V3-specific antibodies. J Gen Virol. 79:(1):1998;77-82. [January].
26. Bunce M., O'Neill C.M., Barnardo M.C.N.M., Krausa P., Browning M.J., Morris P.J., et al. Phototyping: comprehensive DNA typing for HLA-A, B, C, DRB1, DRB3, DRB4, DRB5 & DQB1 by PCR with 144 primer mixes utilizing sequence-specific primers (PCR-SSP). Tissue Antigens. 46:(5):1995;355-367.
27. Carmichael A., Jin X., Sissons P. Analysis of the human env-specific cytotoxic T-lymphocyte (CTL) response in natural human immunodeficiency virus type 1 infection: low prevalence of broadly cross-reactive env-specific CTL. J. Virol. 70:(12):1996;8468-8476.
28. Wills M.R., Carmichael A.J., Mynard K., Jin X., Weekes M.P., Plachter B., et al. The human cytotoxic T-lymphocyte (CTL) response to cytomegalovirus is dominated by structural protein pp65: frequency, specificity, and T-cell receptor usage of pp65-specific CTL. J. Virol. 70:(11):1996;7569-7579.
29. Conover WJ. Practical Nonparametric Statistics, 1999.
30. McCormack S, Kepple J, Morgan K, Tilzey A, Brodnicki E, Duff C et al. Definition of a healthy volunteer - reflections from a Phase I HIV vaccine trial. MSSVD Spring meeting, Oxford, July;Poster 53, 1997.
31. Stoute J.A., Slaoui M., Heppner D.G., Momin P., Kester K.E., et al. A preliminary evaluation of a recombinant circumsporozoite protein vaccine against plasmodium falciparum malaria. N. Engl. J. Med. 336:(2):1997;86-91.
32. Moore A., McCarthy L., Mills K.H. The adjuvant monophosphoryl lipid A and QS21 switches T cell responses induced with a soluble recombinant HIV protein from Th2 to Th1. Vaccine. 17:(20-21):1999 Jun 4;2517-2527.
33. Rosenberg E.S., Billingsley J.M., Caliendo A.M., Boswell S.L., Sax P.E., Kalams S.A., et al. Vigorous HIV-1 specific CD4+ T cell responses associated with control of viremia. Science. 21:(2785342):1997;1447-1450.
34. W61D. J. Inf. Dis. 179:(3):1999 Mar;558-566.
35. Pincus S.H., Messer K.G., Cole R., Ireland R., Vancott T.C., Pinter A., et al. Vaccine-specific antibody responses induced by HIV-1 envelope subunit vaccines. J. Immunol. 158:(7):1997;3511-3520.
36. Mascola J.R., Snyder S.W., Weislow O.S., Belay S.M., Belshe R.B., Schwartz D.H., et al. Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. J. Infect. Dis. 173:(2):1996;340-348.
37. Coeffier E., Excler J.-L., Kieny M.P., Meignier B., Moste C., Tartaglia J., et al. Restricted specificity of anti-V3 antibodies induced in humans by HIV candidate vaccines. AIDS Res. Hum. Retroviruses. 13:(17):1997;1471-1485.
38. Levine M.M., Ferreccio C., Black R.E., Tacket C.O., Germanier R. Progress in vaccines against typhoid fever. Rev. Infect. Dis. 11:(Suppl 3):1989;S552-S567. [May-June].
39. Cumberland N.S., StClair-Roberts J., Arnold W.S., Patel R.K., Bowker C.H. Typhoid Vi: a less reactogenic vaccine. J. Int. Med. Res. 20:(3):1992;247-253. [June].